SULFORAPHANE SUPPLEMENTATION INCREASES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN HEMODIALYSIS PATIENTS

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/47b36d1e9b5528eca671c28f7f33f75d.pdf

Abstract Title

First Name *

Ludmila

Last Name *

Cardozo

Co-author 1

Marcia Ribeiro ribeiromarcia.trabalhos@gmail.com Federal University of Rio de Janeiro Graduate Program in Biological Sciences – Physiology Rio de Janeiro

Co-author 2

Michelli Souza eumichellisouza@gmail.com Federal University Fluminense Graduate Program in Cardiovascular Sciences Niterói

Co-author 3

Julie Julie Ann Kemp kemp.julie@gmail.com Federal University Fluminense Graduate Program in Nutrition Sciences NIterói

Co-author 4

Marcelo Marcelo Ribeiro-Alves mribalves@gmail.com National Institute of Infectology Evandro Chagas HIV/AIDS Clinical Research Center Rio de Janeiro

Co-author 5

Denise Mafra dmafra30@gmail.com Federal University of Rio de Janeiro / Federal Fluminense University Graduate Program in Biological Sciences – Physiology/ Graduate Program in Nutrition Sciences Rio de Janeiro

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Chronic Kidney Disease (CKD) patients have cardiovascular diseases as the main cause of death, with dyslipidemia being one of the main risk factors. In this context, non-pharmacological strategies such as the use of sulforaphane (SFN), an isothiocyanate in cruciferous vegetables well-known for its antimicrobial, antioxidant, and anti-inflammatory properties, may emerge as an adjuvant therapeutic alternative to modulate dyslipidemia in CKD. Human and animal studies provide evidence that diets rich in cruciferous vegetables can modify the plasma lipid profile and reduce cardiovascular risk. This study aimed to evaluate the effects of SFN on the lipid profile of patients with CKD on hemodialysis (HD).

Methods

This was a clinical, double-blind, randomized, placebo-controlled trial in which 30 patients on regular HD treatment (3 sessions per week, 4 hours long) for at least six months were included and randomized into two groups: SFN (1 sachet/day 2.5 g containing 1% sulforaphane extract) or placebo (1 sachet/day of corn starch, coloured with chlorophyll) for two months. Blood collections were performed before and after supplementation. Lipid profile and routine biochemical parameters were analyzed using commercial kits (Bioclin).

Results

30 patients completed the study: 14 in the SFN group (57.5 ± 14 years, 7 men, BMI: 25 ± 12.97 kg/m²) and 16 in the placebo group (57 ± 21.25 years, 10 men, BMI: 26.6 ± 5.5 kg/m²). The data revealed that the intervention with SFN significantly increased plasma levels of high-density lipoprotein (HDL) (P=0.038) with no significant differences in the placebo group (Fig 1). No significant changes were also not observed for other lipid-related markers or any routine biochemical parameters.

Conclusions

This preliminary study demonstrated that supplementation with 2.5 g of 1% sulforaphane extract for two months improved plasma HDL levels being a safe coadjuvant strategy for patients with CKD on HD.

Funding Sources/Commercial Support: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível

Superior (CAPES) and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos